Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease (original) (raw)

Abstract

There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis. Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer's disease (AD) biomarkers-β-amyloid 1-42 (Aβ 42 ), total tau (t-tau), phosphorylated tau (p-tau)-differentiate PD patients from controls, and that reduced levels of Aβ 42 represent a predictive factor for development of cognitive deterioration in PD. In this prospective study carried out in 44 PD patients and 25 neurological controls we wanted to verify whether the combination of CSF α-synuclein species-t-α-syn and o-α-syn-and classical AD biomarkers may help in differentiating PD from neurological controls, and if these biomarkers may predict cognitive decline. The median of follow-up duration was 3 years (range: 2-6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used for monitoring cognitive changes along time, being administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic value, significantly contributing to the discrimination of PD from neurological controls. A greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ 42 /tau ratios (Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR = 12.52). Low CSF Aβ 42 level was associated with a higher rate of MMSE and MoCA decline, confirming its role as independent predictive factor for cognitive decline in PD. None of the other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic value. We conclude that combination of CSF o/t-α-syn and Aβ 42 /tau ratios improve the diagnostic accuracy of PD. PD patients showing low CSF Aβ 42 levels at baseline are more prone to develop cognitive decline.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (39)

  1. Aerts, M. B., Esselink, R. A., Abdo, W. F., Bloem, B. R., and Verbeek, M. M. (2012). CSF α-synuclein does not differentiate between parkinsonian disor- ders. Neurobiol. Aging 33, 430.e1-430.e3. doi: 10.1016/j.neurobiolaging.2010. 12.001
  2. Alves, G., Brønnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., et al. (2010). CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatry 81, 1080-1086.doi: 10.1136/jnnp.2009.199950
  3. Balducci, C., Pierguidi, L., Persichetti, E., Parnetti, L., Sbaragli, M., Tassi, C., et al. (2007). Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov. Disord. 22, 1481-1484. doi: 10.1002/mds.21399
  4. Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211. doi: 10.1016/S0197-4580(02)00065-9
  5. Ciaccioli, G., Martins, A., Rodrigues, C., Vieira, H., and Calado, P. (2013). A power- ful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration. PLoS ONE 8:e55848. doi: 10.1371/journal.pone.0055848
  6. Compta, Y., Parkkinen, L., O'Sullivan, S. S., Vandrovcova, J., Holton, J. L., Collins, C., et al. (2011). Lewy-and Alzheimer-type pathologies in Parkinson's dis- ease dementia: which is more important? Brain 134(Pt 5), 1493-1505. doi: 10.1093/brain/awr031
  7. Compta, Y., Martí, M. J., Ibarretxe-Bilbao, N., Junqué, C., Valldeoriola, F., Muñoz, E., et al. (2009). Cerebrospinal tau, phospho-tau, and beta-amyloid and neu- ropsychological functions in Parkinson's disease. Mov. Disord. 24, 2203-2210. doi: 10.1002/mds.22594
  8. Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., Dekosky, S. T., Barberger- Gateau, P., et al. (2010). Revising the definition of Alzheimer's disease: a new lex- icon. Lancet Neurol. 9, 1118-1127. doi: 10.1016/S1474-442270223-442270224
  9. Eusebi, P. (2013). Diagnostic accuracy measures. Cerebrovasc. Dis. 36, 267-272. doi: 10.1159/000353863
  10. Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198. doi: 10.1016/0022-3956(75)90026-6
  11. Gill, D. J., Freshman, A., Blender, J. A., and Ravina, B. (2008). The montreal cog- nitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov. Disord. 23, 1043-1046. doi: 10.1002/mds.22017
  12. Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., et al. (2010). DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133(Pt 3), 713-726. doi: 10.1093/brain/awq008
  13. Irwin, D. J., White, M. T., Toledo, J. B., Xie, S. X., Robinson, J. L., Van Deerlin, V., et al. (2012). Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72, 587-598. doi: 10.1002/ana.23659
  14. Kang, J. H., Irwin, D. J., Chen-Plotkin, A. S., Siderowf, A., Caspell, C., Coffey, C. S., et al. (2013). Association of cerebrospinal fluid β-Amyloid 1-42, T-tau, P- tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70, 1277-1287. doi: 10.1001/jamaneurol. 2013.3861
  15. Leverenz, J. B., Watson, G. S., Shofer, J., Zabetian, C. P., Zhang, J., and Montine, T. J. (2011). Cerebrospinal fluid biomarkers and cognitive performance in non- demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 17, 61-64. doi: 10.1016/j.parkreldis.2010.10.003
  16. Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., and Schlossmacher, M. G. (2011). α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-240. doi: 10.1016/S1474-442270014-X Montine, T. J., Shi, M., Quinn, J. F., Peskind, E. R., Craft, S., Ginghina, C., et al. (2010). CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25, 2682-2685. doi: 10.1002/mds.23287
  17. Noguchi-Shinohara, M., Tokuda, T., Yoshita, M., Kasai, T., Ono, K., Nakagawa, M., et al. (2009). CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 1251, 1-6. doi: 10.1016/j.brainres.2008.11.055
  18. Paleologou, K. E., Kragh, C. L., Mann, D. M., Salem, S. A., Al-Shami, R., Allsop, D., et al. (2009). Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132(Pt 4)1093-1101. doi: 10.1093/brain/awn349
  19. Park, M. J., Cheon, S. M., Bae, H. R., Kim, S. H., and Kim, J. W. (2011). Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. J. Clin. Neurol. 7, 215-222. doi: 10.3988/jcn.2011.7. 4.215
  20. Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., et al. (2013). Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 9, 131-140. doi: 10.1038/nrneurol.2013.10
  21. Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., et al. (2014). Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. Mov. Disord. doi: 10.1002/mds.25772. [Epub ahead of print].
  22. Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., De Carlo, C., Qureshi, M. M., et al. (2011). Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26, 1428-1435. doi: 10.1002/mds.23670
  23. Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D'Amore, C., et al. (2008). Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol. Psychiatry 64, 850-855. doi: 10.1016/j.biopsych.2008.02.016
  24. Pøikrylová Vranová, H., Mareš, J., Nevrlý, M., Stejskal, D., Zapletalová, J., Hluštík, P., et al. (2010). CSF markers of neurodegeneration in Parkinson's disease. J. Neural. Transm. 117, 1177-1181. doi: 10.1007/s00702-010-0462-z R Core Team. (2013). R: A. Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing. Available online at: http:// www.R-project.org/
  25. Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J. C., et al. (2011). pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77. doi: 10.1186/1471- 2105-12-77
  26. Rubin, D. B. (1987). Multiple Imputation for Nonresponse in Surveys. New York, NY; Chichester: Wiley. doi: 10.1002/9780470316696
  27. Siderowf, A., Xie, S. X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., et al. (2010). CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 75, 1055-1061. doi: 10.1212/WNL.0b013e3181
  28. Sierks, M. R., Chatterjee, G., McGraw, C., Kasturirangan, S., Schulz, P., and Prasad, S. (2011). CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr. Biol. (Camb.) 3, 1188-1196. doi: 10.1039/c1ib00018g
  29. Sjögren, M., Davidsson, P., Wallin, A., Granérus, A. K., Grundström, E., Askmark, H., et al. (2002). Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord. 13, 112-118. doi: 10.1159/000048642
  30. Spies, P. E., Slats, D., Rikkert, M. G., Tseng, J., Claassen, J. A., and Verbeek, M. M. (2011). CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans. Neurosci. Lett. 504, 336-338. doi: 10.1016/j.neulet.2011.09.063
  31. Spies, P. E., Melis, R. J., Sjögren, M. J., Rikkert, M. G., and Verbeek, M. M. (2009). Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J. Alzheimers Dis. 16, 363-369. doi: 10.3233/JAD-2009-0955
  32. Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., and Murano, T. (2012). Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 26, 213-216. doi: 10.1097/WAD.0b013e31823899cc
  33. Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A., Kasai, T., et al. (2010). Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766-1772. doi: 10.1212/WNL.0b013e3181fd613b
  34. Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., et al. (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individu- als and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166. doi: 10.1016/j.bbrc.2006.08.024
  35. Tsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., et al. (2008). Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS ONE 3:e3135. doi: 10.1371/journal.pone.0003135
  36. Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J., and Stefanis, L. (2011). Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 10, 1015-1025. doi: 10.1016/S1474-442270213-442270217
  37. Waxman, E. A., and Giasson, B. I. (2011). Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J. Neurosci. 31, 7604-7618. doi: 10.1523/JNEUROSCI.0297-0211.2011
  38. Zhang, J., Mattison, H. A., Liu, C., Ginghina, C., Auinger, P., McDermott, M. P., et al. (2013). Longitudinal assessment of tau and amyloid beta in cere- brospinal fluid of Parkinson disease. Acta Neuropathol. 126, 671-682. doi: 10.1007/s00401-013-1121-x
  39. Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J., Kenney, C., et al. (2008). CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129, 526-529. doi: 10.1309/W01Y0B808EMEH12L